Yao Min, Wang Li, Qiu Liwei, Qian Qi, Yao Dengfu
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Anticancer Agents Med Chem. 2015;15(4):453-60. doi: 10.2174/1871520615666141216150135.
Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies worldwide with poor prognosis. Most of the HCC patients died quickly because of the rapid tumor progression with no effective therapy except for liver resection or transplantation. Recently, microRNAs (miRNAs) have emerged as key factors involved in a series of biological processes ranging from embryogenesis to programmed cell death with aberrant expression profiles, potentially attractive diagnosis, prognosis or therapeutic applications for related-diseases. Accumulating evidences have indicated the roles of miRNAs as tumor suppressor in hepatocyte malignant transformation including development, differentiation, proliferation and tumorigenesis. This article reviews that the recent progress underlies the development of novel miRNA-based HCC therapeutic strategies in the coming future.
肝细胞癌（HCC）是全球最常见且迅速致命的恶性肿瘤之一，预后较差。大多数HCC患者因肿瘤进展迅速而很快死亡，除了肝切除或移植外没有有效的治疗方法。最近，微小RNA（miRNA）已成为一系列生物学过程（从胚胎发生到程序性细胞死亡）中的关键因素，其表达谱异常，对相关疾病具有潜在的有吸引力的诊断、预后或治疗应用价值。越来越多的证据表明，miRNA在肝细胞恶性转化（包括发育、分化、增殖和肿瘤发生）中作为肿瘤抑制因子发挥作用。本文综述了近期的进展，这些进展为未来基于miRNA的新型HCC治疗策略的发展奠定了基础。
